Marker Therapeutics (MRKR) Short-Term Debt repayments (2010 - 2012)
Marker Therapeutics (MRKR) reported Short-Term Debt repayments of $85222.0 for Q4 2012, up 328.25% year-over-year from $19900.0 in Q1 2012, and up 40.22% quarter-over-quarter from $60777.0 in Q3 2012.
Marker Therapeutics (MRKR) Short-Term Debt repayments (2010 - 2012) Analysis & Trends
Marker Therapeutics (MRKR) has 3 years of Short-Term Debt repayments data on file, last reported at $85222.0 in Q4 2012.
- Short-Term Debt repayments for Q4 2012 came in at $85222.0, up 328.25% year-over-year; the trailing twelve-month figure through Dec 2012 was $205543.0 (up 1903.01% YoY), and the FY2012 annual result was $205543.0, up 1903.01% from the prior year.
- Short-Term Debt repayments climbed to $85222.0 in Q4 2012 per MRKR's latest filing, from $60777.0 in the prior quarter.
- Over five years, Short-Term Debt repayments peaked at $101826.0 in Q4 2010 and troughed at -$86100.0 in Q1 2011.
- A 3-year average of $30726.9 and a median of $29772.0 in 2012 frame the typical range for Short-Term Debt repayments.
- The sharpest annual moves came in 2011 and 2012: Short-Term Debt repayments plunged 80.46% in 2011, then surged 1232.55% in 2012.
- A 3-year view of Short-Term Debt repayments shows it stood at $101826.0 in 2010, then sank by 80.46% to $19900.0 in 2011, then jumped by 328.25% to $85222.0 in 2012.
- Business Quant data shows MRKR's Short-Term Debt repayments at $85222.0 in Q4 2012, $60777.0 in Q3 2012, and $38644.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ST Debt Repayment (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 102,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -482,347.21 |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 85,222.00 |
| Dec 31, 2012 | 85,222.00 |
| Sep 30, 2012 | 60,777.00 |
| Sep 30, 2012 | 60,777.00 |
| Jun 30, 2012 | 38,644.00 |
| Jun 30, 2012 | 38,644.00 |
| Mar 31, 2012 | 20,900.00 |
| Mar 31, 2012 | 20,900.00 |
| Dec 31, 2011 | 19,900.00 |
| Dec 31, 2011 | 19,900.00 |
| Sep 30, 2011 | 51,900.00 |
| Sep 30, 2011 | 51,900.00 |
| Jun 30, 2011 | 2,900.00 |
| Jun 30, 2011 | 2,900.00 |
| Mar 31, 2011 | -86,100.00 |
| Mar 31, 2011 | -86,100.00 |
| Dec 31, 2010 | 101,826.00 |
| Dec 31, 2010 | 101,826.00 |
| Sep 30, 2010 | 11,300.00 |
| Sep 30, 2010 | 11,300.00 |